Literature DB >> 15687240

Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1.

Wanli Lei1, Fan Liu, Scott A Ness.   

Abstract

The c-Myb transcription factor controls differentiation and proliferation in hematopoietic and other cell types and has latent transforming activity, but little is known about its regulation during the cell cycle. Here, c-Myb was identified as part of a protein complex from human T cells containing the cyclin-dependent kinase (CDK) CDK6. Assays using model reporter constructs as well as endogenous target genes showed that the activity of c-Myb was inhibited by cyclin D1 plus CDK4 or CDK6 but stimulated by expression of the CDK inhibitors p16 Ink4a, p21 Cip1, or p27 Kip1. Mapping experiments identified a highly conserved region in c-Myb which, when transferred to the related A-Myb transcription factor, also rendered it responsive to CDKs and p27. The results suggest that c-Myb activity is directly regulated by cyclin D1 and CDKs and imply that c-Myb activity is regulated during the cell cycle in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687240      PMCID: PMC1895079          DOI: 10.1182/blood-2004-08-3342

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

Review 1.  Myb proteins in life, death and differentiation.

Authors:  K Weston
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

2.  SMART, a simple modular architecture research tool: identification of signaling domains.

Authors:  J Schultz; F Milpetz; P Bork; C P Ponting
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Cooperation of Myb and Myc proteins in T cell lymphomagenesis.

Authors:  J Davies; P Badiani; K Weston
Journal:  Oncogene       Date:  1999-06-17       Impact factor: 9.867

Review 4.  Myb binding proteins: regulators and cohorts in transformation.

Authors:  S A Ness
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

5.  D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain.

Authors:  B Ganter; S l Fu; J S Lipsick
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

6.  Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities.

Authors:  P Kaldis; A A Russo; H S Chou; N P Pavletich; M J Solomon
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

7.  The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties.

Authors:  M K Saville; R J Watson
Journal:  Oncogene       Date:  1998-11-26       Impact factor: 9.867

8.  Pim-1 kinase and p100 cooperate to enhance c-Myb activity.

Authors:  J D Leverson; P J Koskinen; F C Orrico; E M Rainio; K J Jalkanen; A B Dash; R N Eisenman; S A Ness
Journal:  Mol Cell       Date:  1998-10       Impact factor: 17.970

9.  Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism.

Authors:  J D Leverson; S A Ness
Journal:  Mol Cell       Date:  1998-01       Impact factor: 17.970

10.  Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.

Authors:  J Easton; T Wei; J M Lahti; V J Kidd
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

View more
  19 in total

1.  Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma.

Authors:  H Lu; Y Wang; Y Huang; H Shi; Q Xue; S Yang; S He; H Wang
Journal:  Clin Transl Oncol       Date:  2013-05-09       Impact factor: 3.405

2.  Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2.

Authors:  Sarah L Hockley; Volker M Arlt; Daniel Brewer; Ian Giddings; David H Phillips
Journal:  BMC Genomics       Date:  2006-10-16       Impact factor: 3.969

Review 3.  Cell cycle regulation of hematopoietic stem or progenitor cells.

Authors:  Sha Hao; Chen Chen; Tao Cheng
Journal:  Int J Hematol       Date:  2016-03-23       Impact factor: 2.490

4.  Editorial: Targeting MYB Oncogene Expression in Adenoid Cystic Carcinoma.

Authors:  Scott A Ness
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

5.  Dual Mechanism of Rag Gene Repression by c-Myb during Pre-B Cell Proliferation.

Authors:  Greg A Timblin; Liangqi Xie; Robert Tjian; Mark S Schlissel
Journal:  Mol Cell Biol       Date:  2017-05-31       Impact factor: 4.272

6.  TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs.

Authors:  Lara Rossi; Aysegul V Ergen; Margaret A Goodell
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

7.  miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb.

Authors:  Zeyu Chen; Erietta Stelekati; Makoto Kurachi; Sixiang Yu; Zhangying Cai; Sasikanth Manne; Omar Khan; Xiaolu Yang; E John Wherry
Journal:  Cell Rep       Date:  2017-09-12       Impact factor: 9.423

8.  Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.

Authors:  Feng Fang; Michael A Rycyzyn; Charles V Clevenger
Journal:  Endocrinology       Date:  2008-11-26       Impact factor: 4.736

9.  Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.

Authors:  John P O'Rourke; Scott A Ness
Journal:  Mol Cell Biol       Date:  2008-01-14       Impact factor: 4.272

Review 10.  Myb proteins: angels and demons in normal and transformed cells.

Authors:  Ye Zhou; Scott A Ness
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.